drugset
drugset / Trial / NCT06534671

Diltiazem in Jervell and Lange-Nielsen Syndrome

NCT06534671 ↗

Phase 4 Completed 1 enrolled Vanderbilt University Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This study will test the effect of diltiazem, a calcium channel blocking drug, on the QT interval in patients with Jervell and Lange-Nielsen syndrome. This will be a single IV dose and acute effects (within minutes) will be observed.

Timeline

Start
2024-10-16
Primary completion
2024-10-23
Completion
2024-10-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Diltiazem Small molecule 0.25 mg/kg Intravenous

Indications

Jervell and Lange-Nielsen syndrome